On or around 01/07/2019 (Ongoing date of last review)
Filing Date: January 04, 2019
According to the Complaint, this action stems from a proposed transaction announced on December 3, 2018 (the “Proposed Transaction”), pursuant to which TESARO, Inc. (“TESARO” or the “Company”) will be acquired by GlaxoSmithKline plc.
On December 14, 2018, Defendants filed a Solicitation/Recommendation Statement (the “Solicitation Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Transaction.
The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
Company & Securities Information
Defendant: TESARO, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TSRO
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Richard Scarantino, et al. v. TESARO, Inc., et al.